Goldman Sachs analysts removed Alnylam (ALNY) from the firm’s US Conviction List as part of its monthly update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharmaceuticals Reports Strong TTR Growth Amid Challenges
- Alnylam Pharmaceuticals Launches Promising Phase 3 Study on Nucresiran for hATTR-PN
- Alnylam price target raised to $500 from $490 at Oppenheimer
- Alnylam price target raised to $489 from $449 at Piper Sandler
- Alnylam price target raised to $527 from $460 at Barclays